Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 08:49pm CET

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.

On February 5, 2018, CNBC published an article alleging that “court proceedings could expose potentially damaging documents” related to certain Johnson & Johnson’s talc products. On this news, shares of Johnson & Johnson fell $7.29 per share or over 5%, to close at $130.39 on February 5, 2018. To obtain additional information, go to:

http://www.zlkdocs.com/JNJ-Info-Request-Form-6450

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/18OUTLOOK 2018 : A mother channels a loss unlike any other into a force to help ot..
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
02/16JOHNSON & JOHNSON : New tremfya® (guselkumab) data demonstrates long-term skin c..
PU
02/16THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/16EAT.MOVE.CONNECT. TIP : New website offers personalized cancer info, support
AQ
02/16JOHNSON & JOHNSON : Consumer presents new scientific research at 2018 american a..
PU
02/16JOHNSON & JOHNSON : - ERLEADA, a Next-Generation Androgen Receptor Inhibitor Gra..
AQ
02/16JOHNSON & JOHNSON : williams, ronald a
PU
02/16JOHNSON & JOHNSON : washington, a. eugene
PU
More news
News from SeekingAlpha
02/18RETIREMENT STRATEGY : How To Have Enough And Which Stocks To Own 
02/18THERAVANCE BIOPHARMA : Johnson & Johnson Deal Looks Solid 
02/17STOCKS TO WATCH : Retail Heavyweights To Center Stage 
02/17RETIREMENT STRATEGY : Inflation Is A Scourge On Retirees' Well-Being 
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,76%
P/E ratio 2018 18,20
P/E ratio 2019 17,01
EV / Sales 2018 4,49x
EV / Sales 2019 4,13x
Capitalization 353 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277